Senate Committee on Aging Chairman Sen. Rick Scott (R-Fla.) is raising concerns over Chinese entities participating in U.S. clinical trials and drug approval processes and calling for immediate action from federal health agencies.
In a March 19 letter to federal health authorities, shared with The Epoch Times beforehand, Scott pointed to Bioheng, a China-based clinical-stage company also known as Imviva, as being “reportedly financed by CCP-linked sources,” referring to the acronym for the Chinese Communist Party.
Citing public information, Scott said Bioheng has proposed a model of collecting donor cells in China, engineering the cells to fight certain cancers through what is called chimeric antigen receptor T-cell (CAR-T) therapy, and administering the modified cells to American patients through U.S.-based clinical trials….
Senator Calls on Federal Health Authorities to Review China’s Role in US Drug Trials
